

Lexaria Bioscience Corp.
Form 8-K
February 23, 2017

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **February 17, 2017**

LEXARIA BIOSCIENCE CORP.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of
incorporation)

000-52138

(Commission File Number)

20-2000871

(IRS Employer Identification No.)

156 Valleyview Road, Kelowna, BC Canada

(Address of principal executive offices)

V1X 3M4

(Zip Code)

Registrant's telephone number, including area code **(250) 765-6424**

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 3.02 Unregistered Sales of Equity Securities

On February 17, 2017, Lexaria Bioscience Corp. (the Company or Lexaria) announced it has received US\$57,001.80 from the exercise of stock options previously granted. The stock options were exercised at prices of US \$0.14 and US\$0.2273 for a total of 366,000 common shares being issued. All options are being exercised by third parties who are neither officers nor directors of the Company.

Edgar Filing: Lexaria Bioscience Corp. - Form 8-K

As per a contract entered in July 2016, the Company is obligated to pay a US\$4,000 monthly fee to a director. The Company and the director have agreed to settle the outstanding amount of US\$16,000 for the four months to February 28, 2017 through the issuance of 29,091 restricted common shares.

No commissions or placement fees have been paid related to the funds received from this option exercise. Proceeds will be used for general corporate purposes.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Item 7.01 Regulation FD Disclosure

A copy of the news release announcing that Lexaria has received US\$57,001.80 from the exercise of stock options previously granted. is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

Item 9.01 Financial Statements and Exhibits

99.1 Press Release dated February 17, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LEXARIA BIOSCIENCE CORP.

/s/ Chris Bunka

Chris Bunka

CEO, Principal Executive Officer

Date: February 23, 2017
